Treatment of Disseminated Cytomegalovirus (CMV) in Immunocompetent Patients

First-Line Treatment Options

Intravenous ganciclovir at 5 mg/kg twice daily should be initiated promptly for disseminated CMV infection in immunocompetent patients, as recommended by the Journal of Crohn's and Colitis 2 and Praxis Medical Insights 1
After 3-5 days of IV therapy, if clinical improvement is observed and oral absorption is adequate, transition to oral valganciclovir 900 mg twice daily for the remainder of the 2-3 week course, according to Praxis Medical Insights 1
Treatment should continue for at least 2-3 weeks and until CMV is no longer detected in blood by PCR, as stated by Praxis Medical Insights 1
In cases of severe disseminated CMV infection, discontinuation of any immunosuppressive therapy is recommended to improve outcomes, as suggested by the Journal of Crohn's and Colitis 2

Foscarnet is the recommended alternative for patients with ganciclovir resistance or intolerance, such as severe myelosuppression, according to Praxis Medical Insights 1
For neurological CMV disease, combination therapy with ganciclovir and foscarnet might be preferred as initial therapy to maximize response, despite higher rates of adverse effects, as recommended by MMWR Recommendations and Reports 3 and Praxis Medical Insights 1
Cidofovir can be considered as a third-line agent, though it carries substantial risk of nephrotoxicity, as noted by Praxis Medical Insights 1

Weekly monitoring of CMV viral load by PCR is essential to assess treatment response, as stated by Praxis Medical Insights 1
Renal function should be closely monitored, especially with foscarnet or cidofovir therapy, according to Praxis Medical Insights 1

For patients with severe CMV colitis, IV ganciclovir or foscarnet should be administered for 21-28 days or until symptoms resolve, as recommended by Gut 4

For severe disease with systemic complications, IV ganciclovir 5 mg/kg twice daily is recommended, with consideration for transition to oral therapy after clinical improvement, according to Praxis Medical Insights 1
For life-threatening disease or neurological involvement, combination therapy with ganciclovir and foscarnet may be considered, as suggested by MMWR Recommendations and Reports 3 and Praxis Medical Insights 1

Foscarnet: nephrotoxicity, electrolyte abnormalities, and neurologic dysfunction, as noted by Praxis Medical Insights 1
Cidofovir: substantial nephrotoxicity and potential ocular toxicity, as stated by Praxis Medical Insights 1

Early initiation of therapy is associated with better outcomes, particularly in cases with neurological involvement, pneumonitis, or disseminated disease, as recommended by Praxis Medical Insights 1